TNFRSF11B and chronic kidney disease: To explore whether the aforementioned alterations in bone microarchitecture in the cKD mice, with or without EPO treatment, may also be related to changes in the RANKL/OPG axis, we analyzed the expression of RANKL and OPG in the whole bone (proximal tibia)24 at the end of the treatment period (2 weeks).